Skip to main content
. Author manuscript; available in PMC: 2017 Sep 8.
Published in final edited form as: Pediatr Nephrol. 2016 Apr 5;31(8):1341–1348. doi: 10.1007/s00467-016-3319-3

Fig. 1.

Fig. 1

Change in immunodominant DSA (iDSA) over time in relation to treatment with bortezomib protocol. Data for all patients presented before and after treatment. Six patients with functioning grafts had one year follow up data available. (a) HLA Class I: Of 4 patients with Class I DSAs prior to treatment, 3 had a significant decrease in iDSA mean fluorescence intensity (MFI) after treatment. One patient developed Class I DSA after treatment. Two patients had rebound, 1 patient had resolution, and 3 patients were negative 1 year post-treatment. The iDSA was to the “A” locus in 3 patients and “Cw” in 2 patients. (b) HLA class II: All 7 patients had Class II DSAs and 2 had significant improvement of iDSA after treatment. One patient had resolution of Class II DSA and 5 patients had no significant change in iDSA 1 year post-treatment. The iDSA was to “DQ” in 5 patients and “DR” in 2 patients.